GlassScriptPhysician profile
Kayla L Nelson
NPI 1003267394
$482.50
in general payments reported to CMS, 2019-2025
14 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.05 · 2022: $90.04 · 2023: $72.83 · 2024: $102 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $71.89 | 2024-2025 | Breztri, Tezspire, Airsupra |
| Gilead Sciences, INC. | $71.75 | 2023-2025 | |
| Abbvie INC. | $59.44 | 2021-2024 | |
| Novo Nordisk INC | $42.60 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Corium, LLC | $39.50 | 2023 | Azstarys |
| Medtronic, INC. | $37.77 | 2025 | Interstim |
| Organon LLC | $37.17 | 2021-2023 | Nexplanon |
| Incyte Corporation | $21.01 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $18.13 | 2022 | |
| Biofrontera INC. | $17.63 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.35 | 2022 | |
| Galderma Laboratories, L.P. | $15.98 | 2024 | |
| Alkermes, INC. | $14.96 | 2025 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.